Your browser is no longer supported. Please, upgrade your browser.
LXRX Lexicon Pharmaceuticals, Inc. daily Stock Chart
LXRX [NASD]
Lexicon Pharmaceuticals, Inc.
Index- P/E2.03 EPS (ttm)1.36 Insider Own0.70% Shs Outstand112.60M Perf Week-4.48%
Market Cap311.90M Forward P/E- EPS next Y-2.00 Insider Trans204.40% Shs Float105.23M Perf Month-19.59%
Income165.00M PEG- EPS next Q-0.77 Inst Own- Short Float14.85% Perf Quarter-30.92%
Sales330.70M P/S0.94 EPS this Y5.60% Inst Trans4.72% Short Ratio12.41 Perf Half Y103.68%
Book/sh1.55 P/B1.79 EPS next Y-319.80% ROA54.10% Target Price8.00 Perf Year-49.73%
Cash/sh2.63 P/C1.05 EPS next 5Y- ROE- 52W Range1.13 - 8.39 Perf YTD-33.25%
Dividend- P/FCF2.81 EPS past 5Y4.30% ROI-47.20% 52W High-66.98% Beta1.00
Dividend %- Quick Ratio8.00 Sales past 5Y95.30% Gross Margin99.10% 52W Low146.22% ATR0.20
Employees202 Current Ratio8.10 Sales Q/Q4126.90% Oper. Margin53.50% RSI (14)31.51 Volatility6.40% 5.92%
OptionableYes Debt/Eq1.49 EPS Q/Q849.10% Profit Margin49.90% Rel Volume0.68 Prev Close2.77
ShortableYes LT Debt/Eq1.42 EarningsMar 11 BMO Payout0.00% Avg Volume1.26M Price2.77
Recom2.80 SMA20-9.72% SMA50-26.35% SMA200-29.26% Volume650,788 Change0.00%
Dec-11-19Downgrade Gabelli & Co Buy → Hold
Nov-08-19Downgrade Citigroup Buy → Neutral $3 → $4
Sep-11-19Upgrade Gabelli & Co Hold → Buy $3
Jul-29-19Downgrade Stifel Buy → Hold $10 → $4
Mar-25-19Upgrade Gabelli & Co Sell → Hold
Jul-31-18Reiterated Stifel Buy $24 → $23
Feb-23-18Downgrade Needham Buy → Hold
Feb-14-18Downgrade JP Morgan Neutral → Underweight $10
Mar-01-17Reiterated Wedbush Outperform $33 → $38
Mar-01-17Reiterated H.C. Wainwright Buy $26 → $27
Oct-07-16Initiated H.C. Wainwright Buy $26
Aug-05-16Reiterated Wedbush Outperform $30 → $31
Aug-02-16Initiated Citigroup Buy $21
Mar-02-16Reiterated Wedbush Outperform $26 → $28
Nov-09-15Reiterated Wedbush Outperform $19 → $26
Sep-28-15Upgrade Gabelli & Co Sell → Hold
Sep-18-15Downgrade Gabelli & Co Hold → Sell
Aug-10-15Downgrade JP Morgan Overweight → Neutral
Aug-19-14Downgrade Gabelli & Co Buy → Hold
Jun-26-12Reiterated Stifel Nicolaus Buy $3 → $4
Jan-24-20 03:00PM  Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyls Antiproliferative Effects in Patients With Carcinoid Syndrome GlobeNewswire
Jan-20-20 04:01PM  Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium GlobeNewswire
08:07AM  Is Lexicon Pharmaceuticals (NASDAQ:LXRX) Using Too Much Debt? Simply Wall St.
Jan-09-20 02:50PM  Top Biotech Stocks for Q1 2020 Investopedia
Jan-06-20 06:09PM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
Dec-20-19 08:31AM  Lexicon shares fall on diabetes study data MarketWatch
07:00AM  Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes GlobeNewswire
Dec-19-19 08:28PM  Were Hedge Funds Right About Betting On Lexicon Pharmaceuticals, Inc. (LXRX)? Insider Monkey
Dec-13-19 08:52AM  Implied Volatility Surging for Lexicon (LXRX) Stock Options Zacks
Dec-05-19 12:54PM  How Much is Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) CEO Getting Paid? Simply Wall St. +12.20%
07:00AM  Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211 GlobeNewswire
Dec-03-19 07:00AM  Lexicon Pharmaceuticals Completes Safety Review of Initial Safety Run-in Cohort of TELE-ABC Study, a Phase 2 Clinical Study of Telotristat Ethyl in Biliary Tract Cancer GlobeNewswire
Dec-02-19 11:09AM  Why Lexicon Pharma Shares Are Moving Lower Benzinga -10.48%
09:57AM  FDA denies appeal of decision over Lexicon Pharmas diabetes drug Yahoo Finance Video
07:58AM  UPDATE: Lexicon Pharmaceuticals stock slides 31% after FDA denies appeal of decision relating to diabetes drug MarketWatch
07:00AM  Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDAs Office of New Drugs for Sotagliflozin in Type 1 Diabetes GlobeNewswire
Nov-26-19 04:01PM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire -6.02%
Nov-15-19 11:17PM  Edited Transcript of LXRX earnings conference call or presentation 7-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-14-19 08:09PM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
09:10AM  Are Investors Undervaluing Lexicon Pharmaceuticals (LXRX) Right Now? Zacks
Nov-13-19 08:39AM  Top Ranked Value Stocks to Buy for November 13th Zacks
Nov-07-19 11:15AM  Lexicon Pharmaceuticals (LXRX) Q3 Earnings and Revenues Beat Estimates Zacks
07:00AM  Lexicon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides a Business Update GlobeNewswire
Oct-31-19 04:01PM  Lexicon Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on November 7, 2019 GlobeNewswire
10:34AM  Lexicon Pharmaceuticals (LXRX) to Report Q3 Results: Wall Street Expects Earnings Growth Zacks
Oct-30-19 10:34AM  Is Lexicon Pharmaceuticals, Inc. (LXRX) Going to Burn These Hedge Funds? Insider Monkey
Oct-29-19 07:05AM  NASDAQ: LXRX Investor Notice: Update in Lawsuit against Lexicon Pharmaceuticals, Inc. announced by Shareholders Foundation ACCESSWIRE
Oct-15-19 11:29AM  Introducing Lexicon Pharmaceuticals (NASDAQ:LXRX), The Stock That Tanked 80% Simply Wall St.
Oct-13-19 05:15PM  New Sanofi CEO Looks to Shake Things Up GuruFocus.com
Oct-02-19 04:01PM  Lexicon Pharmaceuticals Announces Poster Presentations at the NANETS Annual Multidisciplinary NET Medical Symposium GlobeNewswire
Sep-30-19 10:05AM  Small Caps Win in September: 5 Best ETFs & Stocks Zacks -12.37%
Sep-23-19 08:54AM  Are Options Traders Betting on a Big Move in Lexicon Pharmaceuticals (LXRX) Stock? Zacks -5.62%
Sep-18-19 08:42AM  Lexicon (LXRX) Catches Eye: Stock Jumps 7.3% Zacks +29.25%
Sep-15-19 11:18AM  The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck Benzinga
Sep-11-19 07:42PM  Woodlands-based pharma co. to receive $260M in drug dispute settlement American City Business Journals +27.91%
09:46AM  Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally Zacks
07:09AM  The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With $260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway Benzinga
Sep-10-19 04:51PM  Sanofi to pay Lexicon $260 mln for terminated partnership Reuters +21.13%
04:01PM  Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting GlobeNewswire
04:01PM  Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi GlobeNewswire
Sep-09-19 03:38PM  Market Sentiment Around Loss-Making Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Simply Wall St.
Sep-05-19 11:12AM  Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class? Motley Fool
Aug-30-19 07:00AM  Lexicon Pharmaceuticals To Present At Upcoming Investor Conference GlobeNewswire
Aug-27-19 01:59AM  Edited Transcript of LXRX earnings conference call or presentation 31-Jul-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-20-19 07:15PM  Lexicon Pharmaceuticals Inc (LXRX) President and CEO Lonnel Coats Bought $54,000 of Shares GuruFocus.com -6.38%
Aug-09-19 07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire +19.53%
Aug-08-19 05:23PM  Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes GlobeNewswire
Jul-31-19 11:36AM  Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates Zacks -18.67%
09:15AM  Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:00AM  Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update GlobeNewswire
Jul-30-19 12:59PM  Lexicon Pharmaceuticals Announces Date Change for Second Quarter 2019 Financial Results Conference Call and Webcast to July 31, 2019 GlobeNewswire
Jul-29-19 04:35PM  Why Cooper Tire & Rubber, Insperity, and Lexicon Pharmaceuticals Slumped Today Motley Fool -70.30%
12:14PM  Here's Why Lexicon Pharmaceuticals Is Collapsing Today Motley Fool
08:53AM  Lexicon's stock loses more than half its value after Sanofi's notice to end alliance MarketWatch
Jul-27-19 05:05AM  Sanofi ends partnership with Lexicon to develop add-on pill for diabetes Reuters
Jul-26-19 05:58PM  UPDATE 1-Sanofi ends partnership with Lexicon to develop add-on pill for diabetes Reuters
05:15PM  Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista (Sotagliflozin) Type 2 Diabetes Phase 3 Program GlobeNewswire
05:05PM  Sanofi ends partnership with Lexicon to develop diabetes drug Reuters
10:15AM  How Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Can Impact Your Portfolio Volatility Simply Wall St.
Jul-25-19 07:00AM  Lexicon Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call and Webcast on August 1, 2019 GlobeNewswire
Jul-22-19 10:31AM  Lexicon Pharmaceuticals (LXRX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-15-19 05:43PM  AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes Zacks
Jun-26-19 02:07PM  Here is What Hedge Funds Think About Lexicon Pharmaceuticals, Inc. (LXRX) Insider Monkey
Jun-13-19 07:21AM  Should You Be Pleased About The CEO Pay At Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Simply Wall St.
Jun-04-19 07:00AM  Lexicon Pharmaceuticals to Present New Clinical Data at 79th American Diabetes Association Scientific Sessions GlobeNewswire
May-23-19 07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
May-08-19 07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
May-07-19 01:38PM  Edited Transcript of LXRX earnings conference call or presentation 1-May-19 12:00pm GMT Thomson Reuters StreetEvents
May-05-19 08:13PM  Heres What Hedge Funds Think About Lexicon Pharmaceuticals, Inc. (LXRX) Insider Monkey
May-01-19 01:16PM  Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates Zacks
11:49AM  Lexicon Pharmaceuticals Inc (LXRX) Q1 2019 Earnings Call Transcript Motley Fool
07:30AM  Lexicon: 1Q Earnings Snapshot Associated Press
07:00AM  Lexicon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides a Business Update GlobeNewswire
Apr-26-19 04:02PM  ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes GlobeNewswire +5.11%
04:01PM  Zynquista now Approved in the European Union for Treatment of Adults With Type 1 Diabetes GlobeNewswire
Apr-25-19 10:34AM  Will Lexicon Pharmaceuticals (LXRX) Report Negative Q1 Earnings? What You Should Know Zacks
07:00AM  Lexicon Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 1, 2019 GlobeNewswire
Apr-03-19 07:07AM  Did You Manage To Avoid Lexicon Pharmaceuticals's (NASDAQ:LXRX) Painful 55% Share Price Drop? Simply Wall St.
Apr-02-19 07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire +5.14%
Apr-01-19 02:20PM  CLASS ACTION UPDATE for LXRX, BRS, WTW and AMR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:20AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm ACCESSWIRE
10:40AM  FINAL DEADLINE - (LXRX) Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action & Deadline: April 1, 2019 ACCESSWIRE
Mar-29-19 03:00PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LXRX, UXIN, AVEO and AMRN GlobeNewswire +5.70%
01:18PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm GlobeNewswire
Mar-28-19 12:15PM  CLASS ACTION UPDATE for LXRX, UXIN and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:43AM  AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes Zacks
Mar-27-19 10:55AM  Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL Zacks
10:28AM  Tyme Technologies, Inc. (TYME), Vale S.A. (VALE) & Lexicon Pharmaceuticals, Inc. (LXRX) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action ACCESSWIRE
10:00AM  Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tyme Technologies, Inc. (TYME), Vale S.A. (VALE) & Lexicon Pharmaceuticals, Inc. (LXRX) GlobeNewswire
Mar-26-19 04:35PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm ACCESSWIRE
04:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - LXRX ACCESSWIRE
Mar-25-19 11:05AM  Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug Zacks -8.71%
10:10AM  AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes Zacks
09:30AM  What's Next for Lexicon Pharmaceuticals? Motley Fool
Mar-22-19 04:46PM  This Pharma Giant Slipped After FDA Rejected Its Diabetes Treatment Investor's Business Daily -21.91%
04:35PM  Why Zuora, Greenbrier, and Lexicon Pharmaceuticals Slumped Today Motley Fool
02:39PM  FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes Reuters
02:16PM  Sanofi: FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin) GlobeNewswire
02:16PM  Lexicon Pharmaceuticals to Host Conference Call and Webcast Today, March 22, 2019 to Provide a Regulatory Update on Sotagliflozin in Type 1 Diabetes GlobeNewswire
02:16PM  FDA Issues Complete Response Letter for Zynquista (sotagliflozin) GlobeNewswire
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase III clinical trials for the treatment of type 1 and type 2 diabetes; LX9211, which is in Phase Ib clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COATS LONNELPresident and CEOSep 18Buy3.1050,000155,000227,539Sep 19 04:28 PM
Santini Alexander AEVP and CCOSep 18Buy3.364,50015,11518,661Sep 19 04:26 PM
COATS LONNELPresident and CEOSep 17Buy3.1350,000156,403177,539Sep 18 04:39 PM
DEBBANE RAYMONDDirectorSep 16Buy2.7293,773254,785313,417Sep 17 05:36 PM
SOBECKI CHRISTOPHER JDirectorSep 16Buy2.5525,00063,718137,293Sep 17 05:27 PM
DEBBANE RAYMONDDirectorSep 13Buy2.469,26922,806219,644Sep 17 05:36 PM
DEBBANE RAYMONDDirectorSep 13Buy2.40197,473474,760210,375Sep 17 05:33 PM
SOBECKI CHRISTOPHER JDirectorSep 13Buy2.4199,249238,750112,293Sep 17 05:23 PM
COATS LONNELPresident and CEOAug 19Buy1.403,0004,194127,539Aug 20 05:02 PM
COATS LONNELPresident and CEOAug 16Buy1.3537,00049,835124,539Aug 20 05:02 PM
Tessmer James FVP, Finance & AccountingAug 02Buy1.1410,00011,40043,368Aug 02 04:15 PM
BARKER SAM LDirectorAug 02Buy1.1824,00028,20052,187Aug 02 04:12 PM